You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation

Article info

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation
Free

Authors

Citation

Alten R, Lorenz H, Mariette X, et al
AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation
Annals of the Rheumatic Diseases 2017;76:1193-1194.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions